Related Experiment Video
Updated: Jun 20, 2026
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
Time between symptom onset and assessment in age-related macular degeneration with subfoveal choroidal
Rainer Schalnus1, Carsten H Meyer, Claudia Kuhli-Hattenbach
1Department of Ophthalmology, Goethe University Frankfurt am Main, Main, Germany. schalnus@em.uni-frankfurt.de
Background:
Therapy delay in neovascular age-related macular degeneration (NV-AMD) is associated with risk of visual deterioration.
Methods:
Retrospective cross section analysis including patients with NV-AMD who received fluorescein angiography (FA). The time elapsed from symptom onset to assessment was analysed in relation to different factors. Inclusion criteria were: age >50 years, symptom onset within 6 months before assessment, no previous AMD therapy, indication for vascular endothelial growth factor inhibitor treatment.
Results:
Mean duration of symptoms was 2.272 +/- 1.683 months (n = 220); percentiles 25, 50, 75 and 90 corresponded to 1, 2, 3 and 5.383 months. A significant increase (p = 0.033) in mean symptom duration was found between age groups 65-74, 75-84 and over 84 years. Privately insured persons (assessment 1.242 +/- 1.060 months after symptom onset; n = 14) received FA 1.083 months earlier (p = 0.0089) than patients with a statutory health insurance (assessment 2.325 +/- 1.661 months after symptom onset; n = 194).
Conclusion:
In order to avoid progressive visual deterioration in patients with NV-AMD earlier assessment of these individuals should be aimed for.
